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ritical of Implantable
ardioverter-Defibrillator Therapy
ung et al. (1) are to be congratulated for their insightful and
eticulous analysis of the literature of randomized trials of
mplantable cardioverter-defibrillator (ICD) therapy. There are 2
dditional points that deserve amplification and to be made
egarding the use of ICDs in clinical practice. First, a material
eakness that cannot be minimized is that beta-blocker therapy
as applied unequally in some of the ICD trials. For example, the
% absolute improvement in survival that Epstein (2) points to as
linically important is almost matched (4.6%) by the beta-blocker
arvedilol (3). This does not negate the conclusion that ICD
herapy may prolong life (as Epstein points out), but it does cast
ome doubt on this conclusion.
This doubt, combined with other factors, has contributed to the
se of the ICD in fewer than the predicted numbers of patients
4,5). Perhaps the most significant other factor limiting the use of
CDs is the presence of comorbid conditions in patients in the
eneral population at a higher rate than the carefully selected
atients in the randomized trial. Studies such as that of Hernandez
t al. (5) exaggerate this underutilization of ICD therapy by
pplying findings from randomized trials to patients who were
issimilar (nearly 10 years older) to patients enrolled in trials and
o patients who would have been excluded from such trials, for
xample, because of azotemia (4–6).
Difficulty in applying ICD therapy comes not only from
oncern about an overestimate of ICD benefit in appropriate
atients, but also from the application of randomized trial data to
he universe of patients, in whom the presence of multiple medical
onditions would have led to their exclusion from such trials. In
hese patients, with other medical conditions competing as causes
f death, the benefit of ICD therapy will likely be less and the
otential for ICD harm may be greater (6).
The findings of underutilization of ICD therapy may well be
he manifestation of the medical community agreeing with Tung
t al. (1) in their assessment of the benefit of ICD therapy (7,8).
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e thank Dr. Stamato for his interest in our paper (1) and we
cho his sentiments. We also appreciate the accompanying edito-
ial by Epstein (2), which provided counterbalancing insights into
his important issue. As electrophysiologists, we all share the
ommon goal of optimizing and refining our current method of
electing at-risk patients who are most likely to benefit and least
ikely to suffer harm from implantable cardioverter-defibrillator
ICD) therapy. At present, our updated guidelines are indeed
ased on the best available evidence, although it is imperative that
e keep these data in perspective. Our assertion regarding dispar-
te low rates of beta blockade in the landmark trials was merely to
llustrate that the net clinical benefit may have been amplified, but
ot to suggest that the entire benefit of ICD can be accounted for
y beta-blocker inequity.
There are at least 2 degrees of separation that contribute to the
ifficulty in generalizing and applying ICD clinical trial data into
he real world. First, there is the discordance between the inclusion
riteria of a study and the actual population that is enrolled. As an
xample, the average enrolled ejection fraction is almost 10% less
han the enrollment cutoff, although published guidelines are
trictly based on inclusion criteria. This point is nicely reiterated by
yerburg (3) in his recent review on defibrillator usage after
yocardial infarction.
Second, there comes the discrepancy between the actual en-
olled population and the patient characteristics seen in the real
orld, thereby amplifying this generalizability gap. As Dr. Sta-
ato points out, patients with noncardiac comorbidities, including
dvanced age, diabetes mellitus, peripheral vascular disease, renal
isease, and pulmonary disease, tend to be under-represented in
linical trials. The potential futility of ICD efficacy in patients with
hronic and end-stage renal disease has been suggested by multiple
etrospective cohort analyses (4–8). Indeed, there exists a discrep-
ncy in the real world between eligibility and implantation rates
9). Dr. Stamato may be correct in asserting that practicing
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March 31, 2009:1162–5hysicians do factor in this generalizability gap by favoring sound
linical judgment over the implementation of broad guidelines.
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eply
mproving patient outcomes requires therapy proven to enhance
uality of life and survival in a cost-effective fashion. Mindful of
his universally accepted notion in contemporary health care, I
elcome the opportunity to respond to Dr. Stamato’s comments on
he articles by Tung et al. (1) and Epstein (2) regarding evidence
upporting implantable cardioverter-defibrillator (ICD) therapy.
First, Dr. Stamato observes that because beta-blocker use is
imilarly underused in clinical trials and clinical practice, he
oncludes that although ICD therapy prolongs life, underutiliza-
ion “does cast some doubt on this conclusion.” The issue is not
hether ICDs prolong life. Multiple prospective randomized trials
ave unequivocally shown that ICDs prolong life in selected
atient populations (3). The real issue is that guidelines are not
ollowed, including both pharmacologic and nonpharmacologic
herapies. To improve outcomes, including quality of life and
urvival, practice must be evidence based; physicians must “get
ith the guidelines.” The best available data regarding quality of
ife and cost effectiveness support ICD use (4,5).
Second, the use of ICDs in “fewer than the predicted number of
atients” is noted by Dr. Stamato. Initial enthusiasm for most new
herapies tends to be tempered by the outcomes in clinical
edicine compared with clinical trails. Optimistic projections onhe implantation rate of ICDs were based on the prevalence ratherhan incidence of primary prevention ICD candidates. Media
ocus on device and lead reliability was not balanced with context
r perspective on the risks and benefits of ICD therapy. In true
ontext, many more patients have been hurt by unnecessary device
emoval and underutilization than injured by device failure (6).
Finally, all physicians agree that we need to more accurately
dentify not only patients who will benefit from device therapy but also
hose who will not, as discussed in my commentary. The excellent
rticles by Buxton et al. (7) and Goldenberg et al. (8) using retrospec-
ive data from the MUSTT (Multicenter UnSustained Tachycardia
rial) and MADIT II (Multicenter Automatic Defibrillator Implan-
ation Trial II) trials have moved us in this direction. Currently there
re ongoing trials addressing this concern (M2Risk [Risk Stratifica-
ion in MADIT II Type Patients], CARISMA [Cardiac Arrhyth-
ias and Risk Stratification After Myocardial Infarction], and the
EST/PREDICTS [Evaluating the Effectiveness of the LifeVest
efibrillator and Improving Methods for Determining the Use of
mplantable Cardioverter Defibrillators] study) (9–11).
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